Pasithea Therapeutics Q2 2026 Earnings Report

Pasithea Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.16
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Pasithea Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.30 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Pasithea Therapeutics Announcement Details

• Quarter: Q2 2026
• Date: 8/13/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Pasithea Therapeutics (NASDAQ:KTTA), Inc. (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders. Pasithea’s research approach centers on human-derived antibodies with tailored specificity and functionality, addressing areas of high unmet need such as severe chronic inflammatory conditions. By applying its platform to a range of targets, Pasithea seeks to advance innovative therapies toward regulatory milestones and strategic partnerships.

Headquartered in Seattle, Washington, Pasithea Therapeutics maintains research and development operations in the Pacific Northwest, with teams dedicated to antibody engineering, translational science and regulatory strategy. The company is led by a management team with experience in biotechnology innovation, clinical development and commercialization, supported by a board of directors and scientific advisors drawn from leading academic and industry institutions. Pasithea continues to explore collaborations with academic centers and pharmaceutical partners to accelerate its therapeutic programs.